Tengion Inc

Tengion — Rodman & Renshaw Conference 2010

22 slides from Tengion's conference presentation, Sep 13, 2010

  1. Slide 1: Rodman & Renshaw Conference September 13, 2010

    Slide 1: Rodman & Renshaw Conference September 13, 2010

    1 Rodman & Renshaw Conference September 13, 2010

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    2 Forward Looking Statements Forward Looking Statements Certain statements in this presentation may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Tengion believes that these statements are based upon reasonable assumptions

  3. Slide 3: Company Highlights

    Slide 3: Company Highlights

    3 Company Highlights Unique and productive regenerative medicine platform § Products harness the body’s natural ability to regenerate Lead clinical product targets patients with bladder cancer § Phase 1 trial underway - two sites now screening patients § Initial enrollment challenges being addressed

  4. Slide 4: Catalyzing Regeneration in the Body

    Slide 4: Catalyzing Regeneration in the Body

    4 Catalyzing Regeneration in the Body Platform agnostic to cell type or biomaterial used INTEGRATED PLATFORM Industrialization Cells Biomaterials Surgical Implantation Humans have limited capacity to regenerate without a stimulus Our platform uniquely catalyzes human tissue regeneration

  5. Slide 5: Tengion Product Pipeline

    Slide 5: Tengion Product Pipeline

    Tengion Product Pipeline Optinization —_Prociinicat ND Phaset Phase it Phase it Lead Platform Programs AdvancedCKD Sy Neo-GI Augment Esophagectory Additional Platform Programs Neo-Bladder Replacement cystectomy Neo-Bladder Augment Spina Bitidla Urge incontinence (laparascopic) Neo-VesselReplacement

  6. Slide 6: Regenerative medicine brought to life.

    Slide 6: Regenerative medicine brought to life.

    Regenerative medicine orought to life.

  7. Slide 7: Urologic Products to Enhance or Replace Bladder

    Slide 7: Urologic Products to Enhance or Replace Bladder

    7 Urologic Products to Enhance or Replace Bladder Benefit of Tengion Products Current Standard of Care Primary Patient Populations (US and EU) Bowel used to create a tube to transport urine from ureters to abdominal wall into ostomy bag Neo-Urinary Conduit Phase I Bladder cancer (20K/yr) Bowel used

  8. Slide 8: Native-like regeneration at three months with no immune rejection

    Slide 8: Native-like regeneration at three months with no immune rejection

    8 Source: Tengion IND #14218; Presented at International Society for Stem Cell Research, 2009 Native-like regeneration at three months with no immune rejection Normal lining Regeneration of normal lining from ureters to skin with no urine absorption and no mucus secretion Junction with ureter Condui

  9. Slide 9: Neo-Urinary Conduit - Phase I Trial

    Slide 9: Neo-Urinary Conduit - Phase I Trial

    9 Neo-Urinary Conduit - Phase I Trial Open label study § 5 patients with bladder cancer requiring bladder removal § Primary assessment on integrity and patency at 1 year Early enrollment challenges being addressed § Second site, Johns Hopkins initiated recently § Protocol amendments to broaden patie

  10. Slide 10: Regenerative medicine brought to life.

    Slide 10: Regenerative medicine brought to life.

    Regenerative medicine orought to life.

  11. Slide 11: Neo-Kidney Augment Overview

    Slide 11: Neo-Kidney Augment Overview

    11 Neo-Kidney Augment Overview Intended to delay the need for dialysis or transplantation 100,000 new dialysis patients each year in the US § 350,000 currently on dialysis § 20% annual mortality Neo-Kidney Augment Overview Intended to delay the need for dialysis or transplantation Bioactive Renal Ce

  12. Slide 12: Kidney Tissue Regeneration in 5/6th Nephrectomized Rats

    Slide 12: Kidney Tissue Regeneration in 5/6th Nephrectomized Rats

    12 Kidney Tissue Regeneration in 5/6 th Nephrectomized Rats Peer reviewed publication demonstrating regeneration and survival advantage Kelley et al, A tubular cell-enriched subpopulation of primary renal cells improves survival and augments kidney function in a rodent model of chronic kidney diseas

  13. Slide 13: Neo-Kidney Augment R&D Program Overview

    Slide 13: Neo-Kidney Augment R&D Program Overview

    13 Neo-Kidney Augment R&D Program Overview Initial data published this month § Bio-active renal cells preserve functional kidney mass, slow progression, improve survival § Aggressive preclinical model of chronic kidney disease Diabetic kidney failure data § New efficacy data in a diabetic, obese, hy

  14. Slide 14: Diabetic Rat Model of Progressive Nephropathy

    Slide 14: Diabetic Rat Model of Progressive Nephropathy

    14 Diabetic Rat Model of Progressive Nephropathy Kidney failure secondary to severe type 2 diabetes STABLE DECLINE FAILURE Age (Weeks) Untreated Obese ZSF1 = intervention targets Aggressive metabolic syndrome with diabetes and obesity – ~50% mortality at ~1 year of age without treatment – Multiple c

  15. Slide 15: Diabetic Rat Model: Evaluating glomerular and tubular functions

    Slide 15: Diabetic Rat Model: Evaluating glomerular and tubular functions

    15 Diabetic Rat Model of Progressive Nephropathy Evaluating glomerular and tubular functions Evaluating change in treated vs. untreated: § sCREAT § uCREAT § uCREAT / sCREAT ratio § BUN § eGFR § uPHOS § sCa++ / uNa+ § uOSM § uSpGr Diabetic Rat Model of Progressive Nephropathy Evaluating glomerular an

  16. Slide 16: Stabilization of renal filtration; Improved survival

    Slide 16: Stabilization of renal filtration; Improved survival

    16 Stabilization of renal filtration Improved survival 100% (5/5) ZSF1 + NKA 60% (3/5) ZSF1 1-Year Survival Treatment Group

  17. Slide 17: Rodent model of CKD after acute injury

    Slide 17: Rodent model of CKD after acute injury

    17 Rodent model of CKD after acute injury Human-derived cells prevent renal failure in CKD nude rats for 3 mo. I-R/G Injury + Human Renal Cells I-R/G Injury Treatment 1 4 12 weeks post-treatment * * * p<0.05 • Chronic Renal Failure due to Ischemia- Reperfusion + Gentamicin (I-R/G) • I-R/G in nude ra

  18. Slide 18: Regenerative medicine brought to life.

    Slide 18: Regenerative medicine brought to life.

    Regenerative medicine orought to life.

  19. Slide 19: IP and Barriers to Entry

    Slide 19: IP and Barriers to Entry

    19 IP and Barriers to Entry Issued patent protection to 2021, plus recent applications pending § 37 US and 130 international patents and patent applications § Core patents cover composition, design and methods of manufacture Plus know-how, trade secrets, and integrated capabilities associated with t

  20. Slide 20: Financial Overview

    Slide 20: Financial Overview

    20 Financial Overview Financial Overview June 30, 2010 Cash and Investments Long-Term Debt Net Loss - YTD Outstanding Shares (March 31 amount assumes conversion of pre-IPO preferred shares into common) $27.4 M $15.3 M $12.9 M 12.4 M § In April 2010, Tengion completed an IPO of 6 million shares § net

  21. Slide 21: Upcoming Milestones / Data

    Slide 21: Upcoming Milestones / Data

    21 Upcoming Milestones / Data Upcoming Milestones / Data Neo-Urinary Conduit § Enrollment update by 3Q quarterly call § Estimating interim data on first patient by January Neo-Kidney Augment § Diabetic kidney failure early intervention: data ISCT, 9/28/10 § Human cells in nude rat kidney failure: da

  22. Slide 22: Regenerative medicine brought to life.

    Slide 22: Regenerative medicine brought to life.

    Regenerative medicine orought to life.

Source: SEC EDGAR · 8-K filed Sep 13, 2010

More decks from Tengion Inc